Personalized Neurostimulation Approach for the Treatment of Depression
Depression currently affects more than 300 million people worldwide, that is an increase of over 18% between 2005 and 2015. Moreover, 50% of major depressions are untreated in Europe, costing about €170Bn per year. Despite subject...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto PLATOSCIENCE
Duración del proyecto: 5 meses
Fecha Inicio: 2019-01-30
Fecha Fin: 2019-06-30
Líder del proyecto
PLATOSCIENCE APS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Depression currently affects more than 300 million people worldwide, that is an increase of over 18% between 2005 and 2015. Moreover, 50% of major depressions are untreated in Europe, costing about €170Bn per year. Despite subject´s relevance, there are not any efficient nor customized treatment options, these falling often within conventional solutions (e.g. cognitive techniques), medication or neurostimulation techniques that do not acknowledge an individual rehabilitation for the patient.
Platoscience has developed the world’s first plug n’ play device based on trans-cranial direct current neurostimulation (tDCS) for a personalised at-home treatment of depression. The patent-protected device, PlatoCure, consists of a portable neurostimulation headset with two programmable electrodes, easy to use and control, connected to an app to be tracked by health professionals and for cloud data collection and predictive analytics to improve individual treatment. PlatoCure also includes online neuroimaging by electroencephalogram (EEG) that enables measuring of electrophysiological data during stimulation. This yields a significant advantage of PlatoCure against competition, strengthening market introduction to become the standard treatment device for moderate to severe depression, yielding benefits for a large group of stakeholders, including patients, medical professionals, hospitals and clinics.
The SME Ph1 will be crucial for: i) establishing partnerships with relevant stakeholders on an international level in the medical segment, ii) setting up a regulatory strategy and iii) developing a clear commercialisation strategy. Hereafter, PlatoScience will be able to start SME Ph 2 focusing on the clinical validation of the device with hospitals and clinics.
Until the end of 2026, we expect a cumulative revenue of €10,1 million, gross profit of €8,25 million and to create 15 qualified new jobs, within 5 years of commercialization.